Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of
advanced kidney cancer. It is also currently being tested in various other cancers. Sorafenib
works by stopping the development of new cancer cells and new blood vessels. By stopping the
growth of new blood vessels around a tumor, it is believed that sorafenib prevents the growth
of kidney cancer tumors.
This is an "open-label" study which means that the patient, the doctor and Bayer Healthcare
will know what tablets the patient is taking. All patients in this study will receive
sorafenib tablets. Sorafenib is taken orally as a tablet (two tablets are taken twice a day).
Treatment with sorafenib will continue until the patient's tumor grows larger or spreads
further or if the patient has intolerable side effects. The dose of sorafenib that the
patient will receive in the study will increase at certain points during the patient's
treatment, as long as the patient is not experiencing side effects and the patient's tumor
has not grown.